Related Experiment Videos

Determinants of transmitral inflow pattern 10-14 days after acute myocardial infarction

A E Aubert1, I K Jang, T Brzostek

  • 1University Hospital Gasthuisberg, Leuven, Belgium.

Coronary Artery Disease
|February 1, 1995
PubMed

Insights

Recombinant tissue plasminogen activator (rTPA) did not alter diastolic function post-myocardial infarction. However, both rTPA and placebo groups showed impaired diastolic function compared to controls, influenced by infarct size and other patient factors.

Area of Science:

  • Cardiology
  • Medical Imaging
  • Pharmacology

Background:

  • Thrombolytic therapy, such as recombinant tissue plasminogen activator (rTPA), is used to treat acute myocardial infarction (AMI).
  • AMI can impair left ventricular function, including diastolic function.
  • Pulsed Doppler is a non-invasive technique to assess cardiac function.

Purpose of the Study:

  • To evaluate the effect of rTPA on left ventricular diastolic function after AMI using pulsed Doppler.
  • To compare diastolic function in patients treated with rTPA, placebo, and healthy controls.
  • To investigate the relationship between infarct size and diastolic function parameters.

Main Methods:

  • A study involving 104 patients with AMI (48 placebo, 56 rTPA) and 36 age-matched controls.
  • Pulsed Doppler was used to measure key diastolic function parameters: early peak diastolic flow velocity, atrial contraction peak, atrial:early ratio, deceleration time, and half-filling fraction.
  • Comparison of Doppler parameters between treatment groups, controls, and subgroups based on infarct size.

Main Results:

  • No significant difference in Doppler parameters was observed between the rTPA and placebo groups.
  • Both AMI treatment groups exhibited significant diastolic dysfunction compared to controls, evidenced by altered early peak velocity, atrial:early ratio, and half-filling fraction.
  • Patients with large infarcts showed a depressed atrial peak velocity. Multivariate analysis identified end-diastolic pressure, age, end-systolic volume, and wall motion as predictors of diastolic function.

Conclusions:

  • rTPA administration did not significantly alter left ventricular diastolic function parameters in patients with AMI compared to placebo.
  • Patients with AMI, regardless of rTPA treatment, exhibit impaired diastolic function compared to healthy individuals.
  • Infarct size and hemodynamic/echocardiographic parameters are key determinants of diastolic dysfunction severity after AMI.
Abstract

Related Concept Videos